Stock Traders Buy Large Volume of Compass Therapeutics Call Options (NASDAQ:CMPX)

Compass Therapeutics, Inc. (NASDAQ:CMPX) was the recipient of some unusual options trading on Friday. Investors purchased 4,010 call options on the company. This is an increase of 115% compared to the average daily volume of 1,869 call options.

Compass Therapeutics Stock Up 4.0%

Shares of Compass Therapeutics stock opened at $0.79 on Friday. The firm has a market cap of $141.64 million, a price-to-earnings ratio of -1.97 and a beta of 1.02. Compass Therapeutics has a 52-week low of $0.73 and a 52-week high of $6.88. The company’s 50-day simple moving average is $1.46 and its 200-day simple moving average is $3.23.

Compass Therapeutics (NASDAQ:CMPX) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.02). Equities research analysts anticipate that Compass Therapeutics will post -0.47 EPS for the current year.

Institutional Trading of Compass Therapeutics

A number of institutional investors have recently modified their holdings of the business. BlackRock Inc. purchased a new position in Compass Therapeutics in the second quarter valued at about $24,707,000. Palo Alto Investors LP acquired a new position in Compass Therapeutics during the second quarter worth about $12,771,670. Squarepoint Ops LLC lifted its holdings in shares of Compass Therapeutics by 1,906.9% in the second quarter. Squarepoint Ops LLC now owns 1,007,507 shares of the company’s stock valued at $2,206,000 after purchasing an additional 957,305 shares in the last quarter. Seven Fleet Capital Management LP lifted its holdings in shares of Compass Therapeutics by 65.4% in the first quarter. Seven Fleet Capital Management LP now owns 940,538 shares of the company’s stock valued at $4,975,000 after purchasing an additional 371,791 shares in the last quarter. Finally, Bank of America Corp DE grew its holdings in Compass Therapeutics by 224.9% during the 1st quarter. Bank of America Corp DE now owns 865,613 shares of the company’s stock valued at $4,579,000 after buying an additional 599,179 shares during the last quarter. 68.43% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on CMPX. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Compass Therapeutics in a report on Thursday, October 15th. Wedbush set a $4.00 price target on shares of Compass Therapeutics in a research note on Wednesday, September 23rd. Lifesci Capital downgraded shares of Compass Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 22nd. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Compass Therapeutics in a report on Wednesday, September 23rd. Finally, Citizens Jmp lowered their price target on Compass Therapeutics to $4.00 and set a “market outperform” rating on the stock in a report on Wednesday, September 23rd. One research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $10.25.

Compass Therapeutics Company Profile

Compass Therapeutics is a clinical-stage biotechnology company focused on developing antibody-based medicines for cancer. The company’s research is centered on therapies designed to activate and direct the immune system against tumor cells, with the goal of improving immune responses in patients with cancer.

Its lead product candidate, CTX-471, is a fully human monoclonal antibody designed to activate CD137, also known as 4-1BB. CD137 is a co-stimulatory receptor found on immune cells, including T cells and natural killer cells.